

LEBENS LAUF

PERSÖNLICHE DATEN

Name, Vorname, Titel:

Illerhaus, Gerald, Prof. Dr. med.

Klinikanschrift

Ärztlicher Direktor
Klinikum Stuttgart
Klinik Hämatologie, Onkologie, Stammzelltransplantation und Palliativmedizin
Stuttgart Cancer Center – Tumorzentrum Eva Mayr-Stihl
Kriegsbergstr.60, 70174 Stuttgart
Tel.: 0711/278-30400 / Fax.: 0711/278-30409
E-Mail: g.illerhaus@klinikum-stuttgart.de

BERUFLICHE TÄTIGKEIT

1997 - 2007

AiP und Assistenzarzt an der Universitätsklinik Freiburg,
Abteilung Innere Medizin I - Hämatologie/Onkologie,
Ärztlicher Direktor: Prof. Dr. R. Mertelsmann

2004

Facharzt für Innere Medizin

2007

Oberarzt

2008

Erlangung der Venia Legendi für das Fach Innere Medizin

2009

Schwerpunkt Hämatologie und Internistische Onkologie

8/2012

Ernennung zum Außerplanmäßigen Professor

Seit 1.11.2012

Ärztlicher Direktor, Klinikum Stuttgart, Stuttgart Cancer Center – Tumorzentrum Eva Mayr-Stihl

Seit 1.1.2013

Ärztlicher Direktor, Klinikum Stuttgart,
Klinik für Hämatologie, Onkologie, Stammzelltransplantation und Palliativmedizin

VORSTAND-/SPRECHER-TÄTIGKEIT

- Vorstandsmitglied der German Lymphoma Alliance (GLA)
- Vorstandsmitglied Kompetenznetz Maligne Lymphome (KML)
- Vorstandsmitglied der Arbeitsgemeinschaft der Hämatologen und Onkologen im Krankenhaus (ADHOK)
- Sprecher des Vorstands des Onkologischen Schwerpunktes Stuttgart (OSP)

MITGLIEDSCHAFTEN

- Kompetenznetz Maligne Lymphome (KML)
- Deutsche Gesellschaft für Hämatologie und Onkologie (DGHO)
- Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK)

- International Extranodal Lymphoma Study Group (IELSG)
- Berufsverband deutscher Internisten (BDI)
- Deutsche Krebsgesellschaft (DKG)
- Arbeitsgemeinschaft für internistische Onkologie (AIO)
- American Society of Hematology (ASH)
- German Lymphoma Alliance (GLA)
- Arbeitsgemeinschaft der Hämatologen und Onkologen im Krankenhaus (ADHOK)

Publikationsliste Prof. Dr. Illerhaus

Originalpublikationen 2018-2022:

- 1.** Opitz P, Zimmermann S, Mc Laughlin AM, Müller L, Fuxius S, **Illerhaus G**, Scherf-Clavel O, Kloft C, Hempel G; ON-TARGET study consortium.
Development and validation of a bioanalytical method for the quantification of axitinib from plasma and capillary blood using volumetric absorptive microsampling (VAMS) and on-line solid phase extraction (SPE) LC-MS.
J Pharm Biomed Anal. 2022 Nov
- 2.** Khwaja J, Kirkwood AA, Isbell LK, Steffanoni S, Goradia H, Pospiech L, Fail T, Nicholson E, Fletcher K, Linton KM, Parsons KE, Elmusharaf N, Eccersley L, Eyre TA, Chaganti S, Smith J, Thakrar N, Kutilina A, Calimeri T, Martinez-Calle N, El-Sharkawi D, Osborne W, **Illerhaus G**, Fox CP, Ferreri AJ, Schorb E, Cwynarski K.
International multicentre retrospective analysis of thiotepa-based autologous stem cell transplantation for secondary central nervous system lymphoma.
Haematologica. 2022 Oct
- 3.** Wendler J, Fox CP, Valk E, Steinheber C, Fricker H, Isbell LK, Neumaier S, Okosun J, Scherer F, Ihorst G, Cwynarski K, Schorb E, **Illerhaus G**.
Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphoma.
BMC Cancer. 2022 Sep
- 4.** Schiemenz C, Lüken S, Klassen AM, Ranjbar M, **Illerhaus G**, Fend F, Heindl LM, Chronopoulos A, Grisanti S, Kakkassery V.
Clinical procedures for intraocular lymphomas.
Ophthalmologie. 2022 Jul
- 5.** Fend F, Bonzheim I, Kakkassery V, Heindl LM, **Illerhaus G**.
[Lymphoma of the eye and its adnexa : Modern pathological diagnostics and systemic treatment].
Ophthalmologie. 2022 Jul
- 6.** Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, Celico C, Falautano M, Nonis A, La Rosée P, Binder M, Fabbri A, Ilariucci F, Krampera M, Roth A, Hemmaway C, Johnson PW, Linton KM, Pukrop T, Gørløv JS, Balzarotti M, Hess G, Keller U, Stilgenbauer S, Panse J, Tucci A, Orsucci L, Pisani F, Zanni M, Krause SW, Schmoll HJ, Hertenstein B, Rummel M, Smith J, Thurner L, Cabras G, Pennese E, Ponzoni M, Deckert M, Politi LS, Finke J, Ferranti A, Cozens K, Burger E, Ielmini N, Cavalli F, Zucca E, **Illerhaus G**; IELSG32 study investigators.
Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial.
Leukemia. 2022 Jul

7. Kama K, La Rosée P, Czock D, Bosch-Schips J, Illerhaus G.

Hemophagocytic Syndrome-Associated Intravascular Large B-cell Lymphoma With Dialysis-Dependent End-Stage Renal Disease Treated With Autologous Stem Cell Transplantation Using a Modified TEAM Regimen.

Cureus. 2022 Jun

8. Filippini Velázquez G, Schiele S, Gerken M, Neumaier S, Hackl C, Mayr P, Klinkhammer-Schalke M, Illerhaus G, Schlitt HJ, Anthuber M, Kröncke T, Messmann H, Märkl B, Schmid C, Trepel M, Müller G, Claus R, Hackanson B.

Predictive preoperative clinical score for patients with liver-only oligometastatic colorectal cancer.

ESMO Open. 2022 Jun

9. Mc Laughlin AM, Schmulenson E, Teplytska O, Zimmermann S, Opitz P, Groenland SL, Huitema ADR, Steeghs N, Müller L, Fuxius S, Illerhaus G, Joerger M, Mayer F, Fuhr U, Holdenrieder S, Hempel G, Scherf-Clavel O, Jaehde U, Kloft C, For The On-Target Study Consortium.

Developing a Nationwide Infrastructure for Therapeutic Drug Monitoring of Targeted Oral Anticancer Drugs: The ON-TARGET Study Protocol.

Cancers (Basel). 2021 Dec

10. Schorb E, Isbell LK, Illerhaus G, Ihorst G, Meerpohl JJ, Grummich K, Nagavci B, Schmucker C. Treatment Regimens for Immunocompetent Elderly Patients with Primary Central Nervous System Lymphoma: A Scoping Review.

Cancers (Basel) 2021 Aug

11. Nelde A, Maringer Y, Bilich T, Salih HR, Roerden M, Heitmann JS, Marcu A, Bauer J, Neidert MC, Denzlinger C, Illerhaus G, Aulitzky WE, Rammensee HG, Walz JS.

Immunopectidomics-Guided Warehouse Design for Peptide-Based Immunotherapy in Chronic Lymphocytic Leukemia.

Front Immunol. 2021 Jul

12. Kiani A, Roesch R, Wendtner CM, Kullmann F, Kubin T, Südhoff T, Augustin M, Schaich M, Müller-Naendrup C, Illerhaus G, Hartmann F, Hebart H, Seggewiss-Bernhardt R, Bentz M, Späth-Schwalbe E, Reimer P, Kaiser U, Kapp M, Graeven U, Chemnitz JM, Baesecke J, Lambertz H, Naumann R.

Preinfection laboratory parameters may predict COVID-19 severity in tumor patients.

Cancer Med. 2021 Jul

13. Barajas RF, Politi LS, Anzalone N, Schöder H, Fox CP, Boxerman JL, Kaufmann TJ, Quarles CC, Ellingson BM, Auer D, Andronesi OC, Ferreri AJM, Mrugala MM, Grommes C, Neuwelt EA, Ambady P, Rubenstein JL, Illerhaus G, Nagane M, Batchelor TT, Hu LS.

Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG).

Neuro Oncol. 2021 Jul

14. Link H, Illerhaus G, Martens UM, Salar A, Depenbusch R, Köhler A, Engelhardt M, Mahlmann S, Zaiss M, Lammerich A, Bias P, Buchner A.

Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia study.

Support Care Cancer. 2020 Sep

15. Haas M, Waldschmidt DT, Stahl M, Reinacher-Schick A, Freiberg-Richter J, Fischer von Weikersthal L, Kaiser F, Kanzler S, Frickhofen N, Seufferlein T, Dechow T, Mahlberg R, Malferttheiner P, Illerhaus G, Kubicka S, Abdul-Ahad A, Snijder R, Kruger S, Westphalen CB, Held S, von Bergwelt-Baildon M, Boeck S, Heinemann V.

Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomized, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the “burden of therapy” method.

Eur J Cancer 2021 Mar

16. Illerhaus G

CNS relapse in DLBCL: a calculable risk?

Blood 2021 Feb

17. Montesinos-Rongen M, Brunn A, Tuchscherer A, Borchmann P, Schorb E, Kasenda B, Altmüller J, Illerhaus G, Ruge MI, Maarouf M, Büttner R, Hansmann ML, Hallek M, Prinz M, Siebert R, Deckert M.

Analysis of Driver Mutational Hot Spots in Blood-Derived Cell-Free DNA of Patients with Primary Central Nervous System Lymphoma Obtained before Intracerebral Biopsy.

J Mol Diagn. 2020 Oct

18. Schorb E, Kasenda B, Ihorst G, Scherer F, Wendler J, Isbell L, Fricker H, Finke J, Illerhaus G. High-dose chemotherapy and autologous stem cell transplant in elderly patients with primary CNS lymphoma: a pilot study.

Blood Adv. 2020 Jul

19. Lauer EM, Waterhouse M, Braig M, Mutter J, Bleul S, Duque-Afonso J, Duyster J, Marks R, Reinacher PC, Prinz M, Illerhaus G, Finke J, Schorb E, Scherer F.

Ibrutinib in patients with relapsed/refractory central nervous system lymphoma: A retrospective single-centre analysis.

Br J Haematol. 2020 Jul

20. Schorb E, Fox CP, Kasenda B, Linton K, Martinez-Calle N, Calimeri T, Ninkovic S, Eyre TA, Cummin T, Smith J, Yallop D, De Marco B, Krampera M, Trefz S, Orsucci L, Fabbri A, Illerhaus G, Cwynarski K, Ferreri AJM.

Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system - an international study of feasibility and efficacy in routine clinical practice.

Br J Haematol. 2020 Jun

21. Schmitt AM, Herbrand AK, Fox CP, Bakunina K, Bromberg JEC, Cwynarski K, Doorduijn JK, Ferreri AJM, Illerhaus G, Issa S, Schorb E, Zucca E, Hemkens LG, Schandelmanier S, Kasenda B. Rituximab in primary central nervous system lymphoma-A systematic review and meta-analysis

Hematol Oncol. 2019 Aug

- 22.** Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, Kopp HG, Mayer F, Haag GM, Luley K, Lindig U, Schmiegel W, Pohl M, Stoehlmacher J, Folprecht G, Probst S, Prasnikar N, Fischbach W, Mahlberg R, Trojan J, Koenigsmann M, Martens UM, Thuss-Patience P, Egger M, Block A, Heinemann V, **Illerhaus** G, Moehler M, Schenk M, Kullmann F, Behringer DM, Heike M, Pink D, Teschendorf C, Löhr C, Bernhard H, Schuch G, Rethwisch V, von Weikersthal LF, Hartmann JT, Kneba M, Daum S, Schulmann K, Weniger J, Belle S, Gaiser T, Oduncu FS, Güntner M, Hozaeel W, Reichart A, Jäger E, Kraus T, Mönig S, Bechstein WO, Schuler M, Schmalenberg H, Hofheinz RD; FLOT4-AIO Investigators
 Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomized, phase 2/3 trial
Lancet. 2019 May
- 23.** Schorb E, Finke J, Ihorst G, Kasenda B, Fricker H, **Illerhaus** G.
 Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients
BMC Cancer. 2019 Mar
- 24.** Brandt A, Matschke J, Fehrle W, von Wenserski L, Bokemeyer C, Illerhaus G, Binder M.
 A significant proportion of patients with primary central nervous system lymphoma harbor clonal bone marrow B-cells.
Leuk Lymphoma. 2019 Feb
- 25.** Schorb E, **Illerhaus** G, Finke J.
 Current Treatment Standards in PCNSL
Dtsch Med Wochenschr. 2019 Feb
- 26.** Kasenda B, **Illerhaus** G.
 CNS border posts against rituximab?
Lancet Oncol. 2019 Jan
- 27.** Thurner L, Preuss KD, Bewarder M, Kemele M, Fadle N, Regitz E, Altmeyer S, Schormann C, Poeschel V, Ziepert M, Walter S, Roth P, Weller M, Szczepanowski M, Klapper W, Monoranu C, Rosenwald A, Möller P, Hartmann S, Hansmann ML, Mackensen A, Schäfer H, Schorb E, **Illerhaus** G, Buslei R, Bohle RM, Stilgenbauer S, Kim YJ, Pfreundschuh M.
 Hyper N-glycosylated SAMD14 and neurabin-I as driver CNS autoantigens of PCNSL
Blood. 2018 Sep
- 28.** Brandt A, Matschke J, Fehrle W, von Wenserski L, Bokemeyer C, **Illerhaus** G, Binder M.
 A significant proportion of patients with primary central nervous system lymphoma harbor clonal bone marrow B-cells
Leuk Lymphoma. 2018 Jul
- 29.** von Baumgarten L, **Illerhaus** G, Korfel A, Schlegel U, Deckert M, Dreyling M.
 The Diagnosis and Treatment of Primary CNS Lymphoma
Dtsch Arztebl Int. 2018 Jun
- 30.** **Illerhaus** G, Schorb E, Kasenda B.
 Novel agents for primary central nervous system lymphoma: evidence and perspectives.
Blood. 2018 Aug